Emergent BioSolutions, Mount Sinai to test COVID-19 blood plasma as preventive

Emergent BioSolutions (EBS +5.4%) is partnering with Mount Sinai to test its experimental COVID-19 hyperimmune globulin treatment, COVID-HIG, derived from the blood plasma of recovered Covid-19 patients.

The trial is being funded with $34.6M from the Department of Defense, and will focus on whether the drug can be used to prevent COVID-19 infections in physicians, nurses and military personnel.

Under the agreement, ImmunoTek Bio Centers will provide Mount Sinai with collection machines to gather plasma from recovered COVID-19 survivors. Mount Sinai will then ship the plasma to Emergent, which will use it to manufacture COVID-HIG.

https://seekingalpha.com/news/3589567-emergent-biosolutions-mount-sinai-to-test-covidminus-19-blood-plasma-preventive-treatment